BioCryst Pharmaceuticals, Inc. (BCRX)
8.37
-0.37
(-4.23%)
USD |
NASDAQ |
May 21, 16:00
8.32
-0.05
(-0.60%)
After-Hours: 19:59
BioCryst Pharmaceuticals Research and Development Expense (TTM) : 187.06M for March 31, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Anika Therapeutics, Inc. | 26.42M |
| KalVista Pharmaceuticals, Inc. | 48.42M |
| Revolution Medicines, Inc. | 1.117B |
| Plus Therapeutics, Inc. | 9.488M |
| Perspective Therapeutics, Inc. | 77.61M |